William Smith, MD of Mount Sinai addresses the next steps in radiation therapy on the objective response and outcomes in nivolumab for hepatocellular carcinoma.
_____
Among patients with unresectable hepatocellular carcinoma who received combination upfront RT and nivolumab, we found the objective response rate (as determined by mRECIST criteria) to be 35%, substantially increased from historical controls, suggesting that this approach may increase the proportion of patients that would benefit from immune checkpoint inhibition.